Eucure Biopharma will retain the global rights to develop and market YH008 outside Greater China. Credit: mwoot / Pixabay.

Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma and Shenzhen Chipscreen Biosciences’ holding subsidiary Chipscreen NewWay Biosciences have entered an exclusive licensing agreement for YH008, a bispecific antibody.

Under the deal terms, Chipscreen NewWay will develop and commercialise YH008 in Greater China, including Macau, Mainland China, Taiwan, and Hong Kong.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Eucure Biopharma will retain the global rights for the development and commercialisation of the antibody outside Greater China.

Chipscreen NewWay will make a $5.74m (¥40m) upfront payment to Eucure Biopharma and up to $51.7m (¥360m) in potential development milestone payment.

Eucure Biopharma will receive up to $28.17m (¥196m) in potential sales milestone payment and tiered royalties on net sales.

Biocytogen’s independently developed bispecific antibody, YH008, exerts antagonistic and agonistic activities.

It was engineered with an Fc-silent IgG1 isotype to avoid activation of Fc-receptor-mediated non-specific immune.

The bispecific antibody was found to conditionally activate the immune pathway in the tumour microenvironment in vitro and in vivo trials.

It also activated tumour-infiltrating DCs and T cells in vivo pharmacodynamic studies.

Biocytogen Pharmaceuticals president and CEO Dr Yuelei Shen said: “Chipscreen Biosciences and Chipscreen NewWay have extensive experience in clinical drug development and commercialisation.

“With this agreement in place, we will work together to accelerate YH008’s entry into the market to benefit patients.”

The US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) have accepted the investigational new drug (IND) application for a Phase I trial of YH008.

Chipscreen Biosciences CEO and president Dr Xianping Lu said: “Biocytogen’s YH008 has unique mechanisms and outstanding preclinical results.

“This licensing agreement will expand Chipscreen NewWay’s pipeline in the field of antibody drugs and immuno-oncology.”

Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.